The US FDA has granted regulatory approval for landiolol, a beta-adrenergic blocker, to reduce ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter. Clinical evidence In five clinical trials conducted on 317 adult patients, landiolol significantly reduced heart rate in 40 to 90% of patients within ten minutes, compared to 0 to 11% of those given a placebo.
Dosage and administration Available as a lyophilized powder for IV infusion Should be titrated according to ventricular rate For normal cardiac function – Initiate at 9 mcg/kg/min; adjust the dose in 10-min intervals as required in increments of 9 mcg/kg/min to a maximum of 36 mcg/kg/min For impaired cardiac function – Initiate at 1 mcg/kg/min; adjust the dose in 15-min intervals as required in increments of 1 mcg/kg/min to a maximum of 36 mcg/kg/min Contraindications Severe…
